{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:49:29Z","timestamp":1765374569084,"version":"3.46.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"DOI":"10.1007\/s13691-025-00788-5","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:43:06Z","timestamp":1757353386000},"page":"440-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small cell bladder carcinoma with a high tumor mutational burden responding to sequential cisplatin\u2013etoposide and pembrolizumab: a case report"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4757-4633","authenticated-orcid":false,"given":"Akira","family":"Ohtsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Fujizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-735X","authenticated-orcid":false,"given":"Seiji","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Imanari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Agata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Onose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8094-4524","authenticated-orcid":false,"given":"Yoshitaka","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-7273","authenticated-orcid":false,"given":"Kazuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"issue":"1","key":"788_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000052417","volume":"39","author":"I Trias","year":"2001","unstructured":"Trias I, Algaba F, Condom E, Espa\u00f1ol I, Segarra J, Orsola A et al (2001) Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 39(1):85\u201390. https:\/\/doi.org\/10.1159\/000052417","journal-title":"Eur Urol"},{"issue":"3","key":"788_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1159\/000509747","volume":"13","author":"OTD Nguyen","year":"2020","unstructured":"Nguyen OTD, Sundstr\u00f8m SH, Westvik GS, R\u00f8ttereng AKS, Melhus MR, Bergseth C et al (2020) Major durable response of pembrolizumab in chemotherapy refractory small cell bladder cancer: a case report. Case Rep Oncol 13(3):1059\u20131066. https:\/\/doi.org\/10.1159\/000509747","journal-title":"Case Rep Oncol"},{"issue":"4","key":"788_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/iju5.12208","volume":"3","author":"T Hatayama","year":"2020","unstructured":"Hatayama T, Hayashi T, Matsuzaki S, Masumoto H, Yanai H, Abdi H et al (2020) Successful treatment of recurrent small cell carcinoma of urinary bladder with pembrolizumab: a case report. IJU Case Rep 3(4):252\u2013256. https:\/\/doi.org\/10.1002\/iju5.12208","journal-title":"IJU Case Rep"},{"key":"788_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3332\/ecancer.2021.1306","volume":"15","author":"MM Queiroz","year":"2021","unstructured":"Queiroz MM, de Souza ZS, Gongora ABL et al (2021) Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor. ecancermedicalscience 15:1306. https:\/\/doi.org\/10.3332\/ecancer.2021.1306","journal-title":"ecancermedicalscience"},{"issue":"8","key":"788_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/CAD.0000000000001464","volume":"34","author":"J Jin","year":"2023","unstructured":"Jin J, Li J, Peng C et al (2023) Durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment: a case report. Anticancer Drugs 34(8):797\u2013802. https:\/\/doi.org\/10.1097\/CAD.0000000000001464","journal-title":"Anticancer Drugs"},{"issue":"10","key":"788_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353\u20131365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9","journal-title":"Lancet Oncol"},{"key":"788_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008638","volume":"12","author":"JW Kim","year":"2024","unstructured":"Kim JW, Lee HJ, Lee JY et al (2024) Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06). J Immunother Cancer 12:e008638. https:\/\/doi.org\/10.1136\/jitc-2023-008638","journal-title":"J Immunother Cancer"},{"issue":"12","key":"788_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"issue":"8","key":"788_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","volume":"29","author":"JH Hoffman-Censits","year":"2021","unstructured":"Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM et al (2021) Expression of Nectin-4 in bladder urothelial carcinoma and in morphologic variants and non-urothelial histotypes. Appl Immunohistochem Mol Morphol 29(8):619\u2013625. https:\/\/doi.org\/10.1097\/PAI.0000000000000938","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"Suppl 2","key":"788_CR10","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","volume":"22","author":"MB Amin","year":"2009","unstructured":"Amin MB (2009) Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 22(Suppl 2):S96\u2013S118. https:\/\/doi.org\/10.1038\/modpathol.2009.26","journal-title":"Mod Pathol"},{"issue":"9","key":"788_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-230185","volume":"12","author":"S Qayoom","year":"2019","unstructured":"Qayoom S, Chakrabarti D, Khan F, Goel MM (2019) Primary small cell carcinoma of the urinary bladder. BMJ Case Rep 12(9):e230185. https:\/\/doi.org\/10.1136\/bcr-2019-230185","journal-title":"BMJ Case Rep"},{"issue":"6","key":"788_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.euf.2024.06.007","volume":"10","author":"D Robesti","year":"2024","unstructured":"Robesti D, Moschini M, Pio Tenace N, Burgio G, Re C, Leni R et al (2024) The impact of second opinion expert pathology review in patient management at the time of transurethral resection of the bladder. Eur Urol Focus 10(6):1043\u20131048. https:\/\/doi.org\/10.1016\/j.euf.2024.06.007","journal-title":"Eur Urol Focus"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-025-00788-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-025-00788-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-025-00788-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:54:13Z","timestamp":1765371253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-025-00788-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":12,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s13691-025-00788-5","relation":{},"ISSN":["2192-3183"],"issn-type":[{"type":"electronic","value":"2192-3183"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This case report was approved by our institutional ethical committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient to publish this report and any accompanying images. Proof of consent to publish from the study participant can be requested at any time.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}